|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A critical function for type I interferons in cancer immunoediting 显示文摘 | Dunn GP Bruce AT Sheehan KC | 2005 | Nat Immunol2005，6，： | 1 |
| 2 | Elevated circulating levels of matrix,metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease显示文摘 | Zeng B Prasan A Fung KC Solanki V Bruce D Freedman SB | 2005 | Intern Med J2005，35，6： | 1 |
| 3 | Stathmin/oncoprotein 18,a microtubule regulatory protein,is required for survival if both normal and cancer cell lines lacking the tumor suppressor,p53显示文摘 | Bruce KC Cassimeris L | 2010 | Cancer Bip Ther2010，9，9： | 1 |
| 4 | A critical function for type I interferons in cancer immunoediting 显示文摘 | Dunn GP Bruce AT Sheehan KC Shankaran V Uppaluri R Bui JD | 2005 | Nat Immunol2005，6，7： | 1 |
| 5 | Spirituality and well-being:An exploratory study of the patient perspective显示文摘 | Timothy PD Ann KC Bruce BF | | 0，，： | 1 |
| 6 | Inhibitory effect of boldine on fish oil oxidation显示文摘 | Alfonso V Susana N Bruce KC | 1991 | Journal of the Ame-rican Oil Chemists Society1991，68，12： | 1 |
| 7 | A critical function for type I interferons in cancer immunoediting显示文摘 | Dunn GP Bruce AT Sheehan KC | 2005 | Nat Immunol2005，6，7： | 1 |
| 8 | A critical function for type I interferons in cancer immunoediting 显示文摘 | Dunn GP Bruce AT Sheehan KC | 2005 | Nat Immunol2005，6，7： | 1 |
| 9 | A critical function for type I interferons in cancer immunoediting显示文摘 | Dunn GP Bruce AT Sheehan KC | 2005 | Nat Immunol2005，6，7： | 1 |
| 10 | Glucose metabolic phenotype of pancreatic cancer显示文摘AIM: To construct a global 'metabolic phenotype' of pancreatic ductal adenocarcinoma(PDAC) reflecting tumour-related metabolic enzyme expression.METHODS: A systematic review of the literature was performed using Ovid SP and Pub Med databases using keywords 'pancreatic cancer' and individual glycolytic and mitochondrial oxidative phosphorylation(MOP) enzymes. Both human and animal studies investigating the oncological effect of enzyme expression changes and inhibitors in both an in vitro and in vivo setting were included in the review. Data reporting changes in enzyme expression and the effects on PDAC cells, such as survival and metastatic potential, were extracted to construct a metabolic phenotype. RESULTS: Seven hundred and ten papers were initially retrieved, and were screened to meet the review inclusion criteria. 107 unique articles were identified as reporting data involving glycolytic enzymes, and 28 articles involving MOP enzymes in PDAC. Data extraction followed a pre-defined protocol. There is consistent over-expression of glycolytic enzymes and lactate dehydrogenase in keeping with the Warburg effect to facilitate rapid adenosine-triphosphate production from glycolysis. Certain isoforms of these enzymes were over-expressed specifically in PDAC. Altering expression levels of HK, PGI, FBA, enolase, PK-M2 and LDA-A with metabolic inhibitors have shown a favourable effect on PDAC, thus identifying these as potential therapeutic targets. However, the Warburg effect on MOP enzymes is less clear, with different expression levels at different points in the Krebs cycle resulting in a fundamental change of metabolite levels, suggesting that other essential anabolic pathways are being stimulated. CONCLUSION: Further characterisation of the PDAC metabolic phenotype is necessary as currently there are few clinical studies and no successful clinical trials targeting metabolic enzymes. | Anthony KC Chan Jason IE Bruce Ajith K Siriwardena | 2016 | World Journal of Gastroenterology2016，22，12： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员